Divis Laboratories' Q4 FY 2025-26 Quarterly Results

Result Summary

• Divis Laboratories Ltd reported a 10.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 11.8%.
• Its expenses for the quarter were up by 10.1% QoQ and 12.0% YoY.
• The net profit increased 28.8% QoQ and increased 13.4% YoY.
• The earnings per share (EPS) of Divis Laboratories Ltd - at - during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Divis Laboratories Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the manufacture of active pharmaceutical ingredients (APIs) and intermediates. The company has positioned itself as a reliable supplier to global pharmaceutical giants, leveraging its expertise in complex chemistry solutions. Although the specifics of recent developments are not available, Divis Laboratories is known for its emphasis on research and development, which bolsters its product portfolio and competitive edge. This focus on innovation and quality has earned it a substantial presence in both domestic and international markets, contributing significantly to its financial performance.

Revenue

In the fourth quarter of fiscal year 2026 (Q4FY26), Divis Laboratories Ltd reported a total income of ₹2986.00 crores. This represents a noticeable increase of 10.9% compared to the previous quarter (Q3FY26), where the total income was ₹2692.00 crores. Year-over-year, the total income has grown by 11.8%, rising from ₹2671.00 crores in Q4FY25. This upward trajectory in revenue highlights a robust growth pattern over the year, suggesting consistent demand for the company's offerings.

Profitability

During Q4FY26, Divis Laboratories Ltd achieved a profit before tax of ₹963.00 crores, marking a significant quarter-over-quarter increase of 23.5% from ₹780.00 crores in Q3FY26. Year-over-year, the profit before tax rose by 11.5% from ₹864.00 crores in Q4FY25. The company incurred a tax expense of ₹212.00 crores in Q4FY26, which is 7.6% higher than the previous quarter's tax of ₹197.00 crores, and a 5.0% increase from the ₹202.00 crores recorded in Q4FY25. The profit after tax for Q4FY26 stood at ₹751.00 crores, demonstrating a substantial growth of 28.8% quarter-over-quarter and 13.4% year-over-year, compared to ₹583.00 crores in Q3FY26 and ₹662.00 crores in Q4FY25, respectively.

Operating Metrics

The operating metrics for Divis Laboratories Ltd in Q4FY26 reveal significant performance dynamics. The total expenses for the quarter amounted to ₹2023.00 crores, reflecting a 10.1% increase from ₹1838.00 crores in Q3FY26 and a 12.0% rise from ₹1807.00 crores in Q4FY25. The data provided indicates a zero value for earnings per share (EPS) in Q4FY26, contrasting sharply with an EPS of ₹21.98 in Q3FY26 and ₹24.93 in Q4FY25, showing a 100% decrease. This anomaly in EPS requires further investigation beyond the available data to understand its implications on shareholder value. The financial ratios and specific operating metrics such as P/E ratio, debt-to-equity ratio, and current ratio are not provided, thus limiting a more detailed analysis of operational efficiency and financial health.